Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
27
05
2023
received:
08
05
2023
accepted:
28
07
2023
medline:
29
9
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat. To assess the efficacy of medical treatments for UP. We searched MEDLINE, EMBASE, and CENTRAL on 23 November 2022 for randomised controlled trials (RCTs) of medical therapy for adults with UP. Primary outcomes included induction and maintenance of clinical remission. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for each outcome. We included 53 RCTs (n = 4096) including 46 induction studies (n = 3731) and seven maintenance studies (n = 365). First-line therapies included topical 5-aminosalicylic acid (5-ASA), conventional corticosteroids, budesonide, and oral 5-ASA. Therapy for refractory UP included topical tacrolimus and small molecules. Topical 5-ASA was superior to placebo for induction (RR 2.72, 95% CI 1.94-3.82) and maintenance of remission (RR 2.09, 95% CI 1.26-3.46). Topical corticosteroids were superior to placebo for induction of remission (RR 2.83, 95% CI 1.62-4.92). Topical budesonide was superior to placebo for induction of remission (RR 2.34, 95% CI 1.44-3.81). Combination therapy with topical 5-ASA and topical corticosteroids was superior to topical monotherapy with either agent. Topical tacrolimus was superior to placebo. Etrasimod was superior to placebo for induction (RR 4.71, 95% CI 1.2-18.49) and maintenance of remission (RR 2.08, 95% CI 1.31-3.32). Topical 5-ASA and corticosteroids are effective for active UP. Topical 5-ASA may be effective for maintenance of remission. Tacrolimus may be effective for induction of remission. Etrasimod may be effective for induction and for maintenance of remission. Trials should include UP to expand the evidence base for this under-represented population.
Sections du résumé
BACKGROUND
Ulcerative proctitis (UP) is a common highly symptomatic form of ulcerative colitis that can be difficult to treat.
AIM
To assess the efficacy of medical treatments for UP.
METHODS
We searched MEDLINE, EMBASE, and CENTRAL on 23 November 2022 for randomised controlled trials (RCTs) of medical therapy for adults with UP. Primary outcomes included induction and maintenance of clinical remission. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for each outcome.
RESULTS
We included 53 RCTs (n = 4096) including 46 induction studies (n = 3731) and seven maintenance studies (n = 365). First-line therapies included topical 5-aminosalicylic acid (5-ASA), conventional corticosteroids, budesonide, and oral 5-ASA. Therapy for refractory UP included topical tacrolimus and small molecules. Topical 5-ASA was superior to placebo for induction (RR 2.72, 95% CI 1.94-3.82) and maintenance of remission (RR 2.09, 95% CI 1.26-3.46). Topical corticosteroids were superior to placebo for induction of remission (RR 2.83, 95% CI 1.62-4.92). Topical budesonide was superior to placebo for induction of remission (RR 2.34, 95% CI 1.44-3.81). Combination therapy with topical 5-ASA and topical corticosteroids was superior to topical monotherapy with either agent. Topical tacrolimus was superior to placebo. Etrasimod was superior to placebo for induction (RR 4.71, 95% CI 1.2-18.49) and maintenance of remission (RR 2.08, 95% CI 1.31-3.32).
CONCLUSIONS
Topical 5-ASA and corticosteroids are effective for active UP. Topical 5-ASA may be effective for maintenance of remission. Tacrolimus may be effective for induction of remission. Etrasimod may be effective for induction and for maintenance of remission. Trials should include UP to expand the evidence base for this under-represented population.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Budesonide
51333-22-3
etrasimod
6WH8495MMH
Mesalamine
4Q81I59GXC
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
740-762Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9(2):65-72.
van den Heuvel TR, Jeuring SF, Zeegers MP, van Dongen D, Wolters A, Masclee AAM, et al. A 20-year temporal change analysis in incidence, presenting phenotype and mortality, in the Dutch IBDSL cohort-can diagnostic factors explain the increase in IBD incidence? J Crohn's Colitis. 2017;11(10):1169-1179.
Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Am J Gastroenterol. 2000;95(2):469-473.
Hochart A, Gower-Rousseau C, Sarter H, Fumery M, Ley D, Spyckerelle C, et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut. 2017;66(11):1912-1917.
Kruis W, Brandes J, Schreiber S, Theuer D, Krakamp B, Schütz E, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther. 1998;12(8):707-715.
Kim B, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49(2):177-183.
Lie MR, Kanis SL, Hansen BE, van der Woude CJ. Drug therapies for ulcerative proctitis: systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(11):2157-2178.
Marshall J, Irvine E. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775-781.
Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015;148(4):740-750. e742.
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn's Colitis. 2017;11(7):769-784.
Lie M, Kreijne JE, Dijkstra G, Löwenberg M, van Assche G, West RL, et al. No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative Proctitis. Clin Gastroenterol Hepatol. 2020;18(8):1777-1784.e1772.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons; 2019.
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48.
R Development Core Team. R: a language and environment for statistical computing. https://scholar.google.com/citations?user=yvS1QUEAAAAJ&hl=en&oi=sra. Accessed February, 2020.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:343.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
Anonymous. Betamethasone 17-valerate and prednisolone 21-phosphate retention enemata in proctocolitis. A multicentre trial. Br Med J. 1971;3(5766):84-86.
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16(11):1947-1956.
Ardizzone S, Petrillo M, Antonacci CM, Bianchi PG. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis-a randomized single-blind comparative study. Aliment Pharmacol Ther. 1996;10(6):957-960.
Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tabanelli GM, Miglioli M, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988;10(4):406-409.
Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Color Dis. 1990;5(2):79-81.
Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25(7):663-668.
d'Albasio G, Paoluzi P, Campieri M, Porro BG, Pera A, Prantera C, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. the Italian IBD study group. Am J Gastroenterol. 1998;93(5):799-803.
D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85(9):1079-1082.
Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, et al. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26(9):1237-1249.
Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis a comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995;30(2):164-170.
Gionchetti P, Rizzello F, Venturi A, Brignola C, Ferretti M, Peruzzo S, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997;11(6):1053-1057.
Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93-97.
Gionchetti P, D'Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39(4):291-297.
Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther. 2006;23(2):303-312.
Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000;95(7):1749-1754.
Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100(11):2478-2485.
Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567-1574.
Javadi MR, Daryani NE, Gholami K, Mirmomen S, Foroutan H, Amanlou M, et al. Comparison of sucralfate and hydrocortisone enemas in treatment of active ulcerative proctitis; a double-blind randomized clinical trial. DARU. 2003;11(2):69-73.
Kato S, Kani K, Kurihara H, Ohmori T, Yakabi K. Comparison of rectal with oral mesalazine in the treatment of rectal ulcerative proctitis (correct study). Gastroenterology. 2016;1:S775.
Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, et al. Budesonide suppositories are effective and safe for treating acute ulcerative proctitis. Clin Gastroenterol Hepatol. 2019;17(1):98-106.e104.
Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L, Sobon M, et al. Novel budesonide suppository and standard budesonide rectal foam induce high rates of clinical remission and mucosal healing in active ulcerative Proctitis: a randomised, controlled, non-inferiority trial. J Crohns Colitis. 2022;16(11):1714-1724.
Lamet M, Ptak T, Dallaire C, Shah U, Grace M, Spenard J, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11(7):625-630.
Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 2011;56(2):513-522.
Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S. Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative Proctitis. Clin Gastroenterol Hepatol. 2017;15(8):1248-1255.
Lennard-Jones JE, Baron JH, Connell AM, Jones FA. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut. 1962;3:207-210.
Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut. 1998;42(2):195-199.
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(7):648-657.
Moller C, Kiviluoto O, Santavirta S, Holtz A. Local treatment of ulcerative proctitis with salicylazosulphapyridine (Salazopyrin) enema. Clin Trials J. 1978;15(6):199-203.
Mulder CJ, Endert E, van der Heide H, Houthoff HJ, Wiersinga W, Wiltink EH, et al. Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. An adrenocortical approach. Neth J Med. 1989;35(1-2):18-24.
Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8(6):549-553.
Naganuma M, Aoyama N, Suzuki Y, Nishino H, Kobayashi K, Hirai F, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. J Crohn's Colitis. 2016;10(7):828-836.
Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 2018;53(4):494-506.
Ngô Y, Gélinet JM, Ivanovic A, Kac J, Schénowitz G, Vilotte J, et al. Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial. Gastroenterol Clin Biol. 1992;16(10):782-786.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, et al. Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. J Crohn's Colitis. 2023;17(Supplement 1):i536-i538.
Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14(9):1191-1198.
Rufle W, Fruhmorgen P, Huber W, Kimmig JM. Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study. Z Gastroenterol. 2000;38(4):287-293.
Sandberg-Gertzén H, Järnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986;90(4):1024-1030.
Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349(4):350-357.
Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894-1898.
Tarpila S, Turunen U, Seppälä K, Aukee S, Pikkarainen P, Elomaa I, et al. Budesonide enema in active haemorrhagic proctitis-a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther. 1994;8(6):591-595.
Travis SP, Tysk C, de Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut. 1994;35(9):1282-1286.
Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11(8):713-719.
van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21(7):632-635.
van Hogezand RA, van Hees PA, van Gorp JP, van Lier H, Bakker JH, Wesseling P, et al. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988;2(1):33-40.
van der Heide H, van den Brandt-Gradel V, Tytgat GN, Endert E, Wiltink EH, Schipper ME, et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol. 1988;10(2):169-172.
Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation-a placebo-controlled study. Aliment Pharmacol Ther. 2013;38(3):264-273.
Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci. 1987;32(12 Suppl):71S-75S.
Williams CN. Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: a review of two double-blind, placebo controlled trials. Can J Gastroenterol. 1990;4(7):472-475.
Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929-2933.
Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31(11):1178-1185.
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, et al. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative Proctitis. Clin Gastroenterol Hepatol. 2020;18(3):620-627.e621.
Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort. United European Gastroenterol J. 2020;8(8):933-941.
Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis. 2022;16(6):922-930.
Raja SS, Bryant RV, Costello SP, Barnett M, Schubert J, Rayner CK. Systematic review of therapies for refractory ulcerative proctitis. J Gastroenterol Hepatol. 2023;38(4):496-509.
Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, et al. IOIBD recommendations for clinical trials in ulcerative Proctitis: the PROCTRIAL consensus. Clin Gastroenterol Hepatol. 2022;20(11):2619-2627.e2611.
Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut. 2021;70(7):1203-1209.